Clinical Validation of CD Diagnostics Synovasure PJI ELISA Test and Synovasure PJI Lateral Flow Test for Detection of Periprosthetic Joint Infection in Synovial Fluid
Launched by CD DIAGNOSTICS · Aug 11, 2016
Trial Information
Current as of May 21, 2025
Unknown status
Keywords
ClinConnect Summary
A major disadvantage of the MSIS criteria-based definition of PJI is that two of the essential criteria, tissue culture and histological analysis, are only available after surgery. In cases where the surgical samples are critical for the diagnosis of infection, the physician may need to adjust his or her treatment post operatively for the patient based on the treatment provided. The availability of a preoperative test that correlates well with the MSIS criteria could improve patient care. Currently, when a clinician is suspicious of PJI due to pain or failure of an arthroplasty, it is consi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Subject has a total knee and/or hip joint arthroplasty.
- • The subject will be evaluated for revision surgery.
- • o Operative samples are required for full MSIS classification.
- • Subject is ≥22 years of age.
- • Subject has had no recent injections or surgeries of the joint (within past 6 weeks).
- • Subject has or will have all of the medical tests required to allow MSIS classification.
- • Subject signs informed consent form.
- Exclusion Criteria:
- • • Subject does not have a total knee and/or hip joint arthroplasty.
- • Healthy subjects without medical need for aspiration.
- • Subject did not have a revision surgery.
- • Subjects with a diagnostic synovial fluid specimen collection within the past 14 days.
- • Subjects \<22 years of age.
- • Subject has had an injection, lavage, or surgery of the joint within the past 6 weeks.
- • Subject does not have all of the medical tests required for MSIS classification.
- • Subject does not sign informed consent form.
About Cd Diagnostics
CD Diagnostics is a leading clinical trial sponsor dedicated to advancing healthcare through innovative diagnostic solutions. With a focus on developing cutting-edge technologies, CD Diagnostics aims to enhance patient outcomes by facilitating the early detection and management of diseases. The organization collaborates with healthcare providers and research institutions to conduct rigorous clinical trials that adhere to the highest ethical standards and regulatory guidelines. By leveraging a multidisciplinary approach and a commitment to scientific excellence, CD Diagnostics strives to bring transformative diagnostic tools to market, ultimately improving the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials